On Wednesday, Shares of American Express Company (NYSE:AXP), lost -1.39% to $71.20.
American Express Company, declared a regular quarterly dividend of $0.29 per common share, payable on February 10, 2016 to shareholders of record on January 8, 2016.
American Express Company, together with its auxiliaries, provides charge and credit payment card products and travel-related services to consumers and businesses worldwide. The company operates through four segments: U.S. Card Services, International Card Services, Global Commercial Services, and Global Network & Merchant Services.
Shares of Oncothyreon Inc (USA) (NASDAQ:ONTY), inclined 1.72% to $3.55, during its last trading session.
Oncothyreon Inc., declared that it will conduct a conference call on Tuesday, December 8, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss new clinical data from ongoing clinical trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer. The data, which comprise additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive metastatic breast cancer, in addition to an analysis of patients who suffer from central nervous system (CNS) metastases, are slated for presentation during the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.
Finally, Shares of Jabil Circuit, Inc. (NYSE:JBL), ended its last trade with -2.55% loss, and closed at $25.19.
Jabil Circuit, Inc. (JBL), an electronic product solutions company, and Clothing+, attained by Jabil in June 2015, introduced Peak+™, an innovative smart garment reference design for building an integrated textile Heart Rate Monitoring solution at the Wearable Tech Show USA in Santa Clara, California. Jabil and Clothing+ partnered with Suunto, a manufacturer of heart rate monitors; and First beat, a provider of physiological analytics for sports, fitness and wellbeing.
“Building an integrated textile Heart Rate Monitoring solution recently requires very different competencies and capabilities, which often turn into a guessing game between multiple vendors trying to piece it all together,” said John Dargan, Jabil senior vice president. “With Peak+™, we’re offering customers in the fitness, fashion and healthcare markets a strong competitive advantage with a unique, custom solution that gives them easy entry into the high-growth wear ables market.”
Jabil Circuit, Inc., together with its auxiliaries, provides electronic manufacturing services and solutions worldwide. The company operates in two segments, Electronics Manufacturing Services and Diversified Manufacturing Services.